CERECOR INC. (NASDAQ:CERC) Files An 8-K Regulation FD Disclosure

CERECOR INC. (NASDAQ:CERC) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

As previously announced, on September5, 2018, Cerecor Inc. will be presenting at the 20th Annual Global Investment Conference, sponsored by H.C. Wainwright, in New York. A copy of the slide show presentation made at the conference is attached hereto as Exhibit99.1.

The information in this Item 7.01 (including Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Description

99.1

Cerecor Inc. Slide Show Presentation.


Cerecor Inc. Exhibit
EX-99.1 2 a18-24168_1ex99d1.htm EX-99.1 Exhibit 99.1 20th Annual Global Investment Conference,…
To view the full exhibit click here

About CERECOR INC. (NASDAQ:CERC)

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

An ad to help with our costs